COVID-19 scan for 07 July 2022
New cancer drug halves deaths in hospitalized COVID-19 patients The experimental cancer drug sabizabulin slashed all-cause mortality by 55.2% versus placebo in high-risk hospitalized COVID-19 patients for 60 days and was associated with fewer side effects, according to preliminary results from a published phase 3 randomized controlled trial. yesterday at NEJM Evidence . Scientists from sabizabulin manufacturer Veru, Inc. led a multicenter trial of the oral drug, which demonstrated antiviral and anti-inflammatory properties in a preclinical model. These drugs bind to microtubules that are essential for SARS-CoV-2 cell entry and replication and for the massive inflammatory response leading to acute respiratory distress syndrome (ARDS) and death. A total of 204 adults with moderate to severe COVID-19 at high risk for poor outcome were randomly assigned to receive 9 milligrams of sabizabulin or a placebo daily for up to 21 days. The trial was terminated early due to demonstrating drug e